Stephen B. Heitner
Cytel (United States)(US)
Publications by Year
Research Areas
Cardiomyopathy and Myosin Studies, Cardiovascular Function and Risk Factors, Amyloidosis: Diagnosis, Treatment, Outcomes, Cardiovascular Effects of Exercise, Heart Failure Treatment and Management
Most-Cited Works
- → Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis(2018)1,389 cited
- → Correction of a pathogenic gene mutation in human embryos(2017)946 cited
- → Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity(2021)325 cited
- → Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy(2020)323 cited
- → Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry(2019)305 cited
- → Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy(2019)289 cited
- → Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy(2024)246 cited
- → Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy(2019)245 cited
- → Hypertrophic Cardiomyopathy: The Future of Treatment(2020)190 cited
- → Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy(2023)185 cited